仑伐替尼联合经动脉化疗栓塞作为晚期肝细胞癌一线治疗:III期随机临床试验(LAUNCH)
多中心、随机、开放标签、平行分组III期试验显示,在晚期肝细胞癌患者中,仑伐替尼联合按需经动脉化疗栓塞(LEN-TACE)较仑伐替尼单药显著延长中位总生存期(17.8个月 vs 11.5个月;HR 0.45;P<.001),并提高客观缓解率(54.1% vs 25.0%;P<.001)。
要点
- LEN-TACE组中位总生存期17.8个月,仑伐替尼单药组11.5个月,HR 0.45,P<.001。
- LEN-TACE组中位无进展生存期10.6个月,单药组6.4个月,HR 0.43,P<.001。
- LEN-TACE组改良RECIST客观缓解率54.1%,单药组25.0%,P<.001。
核心结论
- 在仑伐替尼基础上联合TACE改善临床结局,是晚期肝细胞癌潜在的一线治疗。
研究设计与样本
- 多中心、随机、开放标签、平行分组III期试验,在中国12个中心纳入338例患者,随机1:1分配至LEN-TACE组170例和仑伐替尼单药组168例。
- 患者为初治或术后首次复发的晚期肝细胞癌;仑伐替尼随机后3天内开始,体重≥60 kg者12 mg每日一次,<60 kg者8 mg每日一次;TACE在仑伐替尼开始后1天启动,按需进行。
- 主要终点为总生存期;在预设的事件驱动中期分析时,中位随访17.0个月。
主要发现
- LEN-TACE组中位总生存期17.8个月,仑伐替尼单药组11.5个月(HR 0.45;P<.001)。
- LEN-TACE组中位无进展生存期10.6个月,仑伐替尼单药组6.4个月(HR 0.43;P<.001)。
- LEN-TACE组改良RECIST客观缓解率54.1%,仑伐替尼单药组25.0%(P<.001)。
- 多变量分析显示门静脉癌栓和治疗分配是总生存期的独立危险因素。
临床怎么用
- 作者认为,在仑伐替尼基础上联合TACE改善临床结局,是晚期肝细胞癌潜在的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN monotherapy in patients with advanced HCC. MATERIALS AND METHODS: This was a multicenter, randomized, open-label, parallel group, phase III trial. Patients with primary treatment-naive or initial recurrent advanced HCC after surgery were randomly assigned (1:1) to receive LEN plus on-demand TACE (LEN-TACE) or LEN monotherapy. LEN was initiated within 3 days after random assignment (initial dose: 12 mg once daily for patients ≥ 60 kg; 8 mg once daily for patients < 60 kg). TACE was initiated one day after LEN initiation. The primary end point was overall survival (OS). RESULTS: Between June 2019 and July 2021, a total of 338 patients underwent random assignment at 12 centers in China: 170 to LEN-TACE and 168 to LEN. At a prespecified event-driven interim analysis after a median follow-up of 17.0 months, the median OS was significantly longer in the LEN-TACE group (17.8 v 11.5 months; hazard ratio, 0.45; P < .001). The median progression-free survival was 10.6 months in the LEN-TACE group and 6.4 months in the LEN group (hazard ratio, 0.43; P < .001). Patients in the LEN-TACE group had a higher objective response rate according to the modified RECIST (54.1% v 25.0%, P < .001). Multivariable analysis revealed that portal vein tumor thrombus and treatment allocation were independent risk factors for OS. CONCLUSION: The addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC.
引用
- Peng Z, Fan W, Zhu B, et al. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol. 2022. PMID: 35921605. doi:10.1200/JCO.22.00392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。